Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1632 1677
This examiner grants 65% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18382048 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | Non-Final OA | President and Fellows of Harvard College |
| 16331772 | METHODS AND COMPOUNDS FOR GENE INSERTION INTO REPEATED CHROMOSOME REGIONS FOR MULTI-LOCUS ASSORTMENT AND DAISYFIELD DRIVES | Non-Final OA | President and Fellows of Harvard College |
| 18253903 | EXPRESSION TECHNOLOGY FOR ANTIBODY CONSTRUCTS | Non-Final OA | Novartis AG |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | Non-Final OA | THE TRUSTEES OF DARTMOUTH COLLEGE |
| 17638753 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | Final Rejection | RIKEN |
| 17373485 | NOVEL AAV8 MUTANT CAPSIDS AND COMPOSITIONS CONTAINING SAME | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17748315 | ENGINEERED MICROBIAL POPULATION | Non-Final OA | Board of Regents, The University of Texas System |
| 17776563 | OPTIDICER CONSTRUCT FOR AGE-RELATED MACULAR DEGENERATION | Non-Final OA | University of Utah Research Foundation |
| 18184517 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | Non-Final OA | STEMCELL TECHNOLOGIES CANADA INC. |
| 16067099 | FLY AVATARS FOR CANCER AND USES THEREOF | Non-Final OA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI |
| 16610471 | PHARMACEUTICAL COMPOSITION AND COSMETIC COMPOSITION | Non-Final OA | Koji TANABE |
| 18491049 | DUAL STRAND NUCLEIC ACID-GUIDED NICKASE EDITING | Non-Final OA | Inscripta, Inc. |
| 16611998 | LIVER ORGANOID COMPOSITIONS AND METHODS OF MAKING AND USING SAME | Final Rejection | Japan Science and Technology Agency |
| 18236218 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF | Non-Final OA | Institute for Research In Biomedicine (IRB) |
| 18025990 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC GLP1R | Non-Final OA | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
| 18025302 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8 | Non-Final OA | BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. |
| 18265421 | TREATMENT OF DANON DISEASE | Non-Final OA | Spacecraft Seven, LLC |
| 17058830 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OSTEOPETROSIS | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18033760 | MODULATING INSULIN EXPRESSION AND PRODUCTION BY TARGETING CD47 | Non-Final OA | WESTERN SYDNEY LOCAL HEALTH DISTRICT |
| 18177298 | PREPARATION METHOD AND APPLICATION OF NON-HUMAN MAMMALS OR THEIR PROGENIES | Non-Final OA | BEIJING LIFE BIOSCIENCES CO., LTD |
| 18003585 | DNA STRUCTURE FOR TREATING OCULAR PATHOLOGIES | Non-Final OA | PULSESIGHT THERAPEUTICS |
| 17788317 | LIVER-SPECIFIC PROMOTER AND APPLICATION THEREOF | Non-Final OA | JINFAN BIOMEDICAL TECHNOLOGY (WUHAN) CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy